News

CRISPR study reveals mitochondrial dysfunction as early marker in amyotrophic lateral sclerosis
Using the gene scissors CRISPR and stem cells, researchers at Stockholm University and the UK Dementia Research Institute (UK ...
SussexWorld7d
New insights into the treatment of ALS: clinical trial results led by Brighton and Sussex Medical School published
Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet. This is ...
Low-dose interleukin-2 added to standard ALS treatment extends patient survival, clinical trial finds
The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard ...
Queen Mary University of London8d
New combination treatment could extend the lifetime of people with amyotrophic lateral sclerosis (ALS)
The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...
Open Access Government8d
Low-dose interleukin-2 found safe and effective for slowing motor neurone disease progression
A clinical trial has found that low-dose interleukin-2 is safe and may significantly extend survival in people with motor ...
Mirage News8d
New ALS Treatment May Extend Patients' Lives
ALS (also known as Motor Neuron Disease (MND)) affects around 45,000 people in Europe at any one time. It attacks the nerves ...
Technology Networks9d
Motor Neuron Disease Drug Safe and Effective at Low Doses
A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease ...
University of Sussex9d
New insights into the treatment of ALS: MIROCALS clinical trial results published in The Lancet
Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.
Mirage News11d
MIROCALS Trial Unveils Breakthrough in MND Treatment
Results of the landmark MIROCALS clinical trial, published in The Lancet, show a low-dose interleukin-2 (IL2LD) is safe, ...
The University of Sheffield11d
Landmark MIROCALS clinical trial provides new insight into treatment of MND
Results of the landmark MIROCALS clinical trial, involving researchers from the University of Sheffield, have revealed new ...
Exercise enhances stem cell transplant function in Parkinson's disease, study finds
Parkinson's disease (PD) is a disabling neurodegenerative disease that affects approximately 10 million people worldwide, ...
Hosted on MSN15d
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
BioRestorative Therapies is a regenerative medicine company that wants to alleviate chronic lower back pain, obesity and diabetes and is developing stem cell therapies to meet that end.